Coherus Biosciences Updates ATM Equity Offering Program

Coherus Biosciences ( (CHRS) ) just unveiled an update.

On January 23, 2026, Coherus Oncology, Inc. filed a prospectus supplement tied to its existing sales agreement with TD Securities (USA) LLC (TD Cowen), updating its plan to periodically issue and sell up to $64.88 million of its common stock. The filing enables the company to raise additional equity capital over time through at-the-market offerings, which may support its ongoing oncology programs and strengthen its financial flexibility, with the legal validity of the stock issuance confirmed by an opinion from Latham & Watkins LLP incorporated into the company’s registration statement.

The most recent analyst rating on (CHRS) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Coherus Biosciences stock, see the CHRS Stock Forecast page.

Spark’s Take on CHRS Stock

According to Spark, TipRanks’ AI Analyst, CHRS is a Neutral.

The score is held back primarily by weak financial performance (sharp revenue decline, negative operating profitability, and persistently negative cash flow). Offsetting this, technicals are favorable with price above key moving averages and positive MACD, and the latest earnings call provided encouraging commercial traction and cost discipline, though execution risks in demand consistency and physician engagement remain.

To see Spark’s full report on CHRS stock, click here.

More about Coherus Biosciences

Coherus Oncology, Inc. operates in the biopharmaceutical sector, focusing on the development and commercialization of oncology-related therapies, with its capital markets activity centered on issuing common stock to fund its operations and growth initiatives.

Average Trading Volume: 1,231,513

Technical Sentiment Signal: Buy

Current Market Cap: $187.4M

See more insights into CHRS stock on TipRanks’ Stock Analysis page.